Advertisement

Topics

These highlights do not include all the information needed to use HYDROXYPROGESTERONE CAPROATE INJECTION safely and effectively. See full prescribing information for HYDROXYPROGESTERONE CAPROATE INJECTION. HYDROXYPROGESTERONE CAPROATE injection, for int | Hydroxyprogesterone Caproate [American Regent, Inc.] | BioPortfolio

12:50 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Hydroxyprogesterone caproate injection is a clear, yellow solution. The solution must be clear at the time of use; replace vial if visible particles or crystals are present.

Hydroxyprogesterone caproate injection single-dose vials are only for intramuscular injection with a syringe into the upper outer quadrant of the gluteus maximus, rotating the injection site to the alternate side from the previous week, using the following preparation and administration procedure:

Intramuscular injection: 250 mg/mL clear yellow solution in single-dose vials.

Do not use hydroxyprogesterone caproate injection in women with any of the following conditions:

Do not use hydroxyprogesterone caproate injection in women with any of the following conditions:

Discontinue hydroxyprogesterone caproate injection if an arterial or deep venous thrombotic or thromboembolic event occurs.

Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of hydroxyprogesterone caproate injection or with other products containing castor oil. Consider discontinuing the drug if such reactions occur.

A decrease in glucose tolerance has been observed in some patients on progestin treatment. The mechanism of this decrease is not known. Carefully monitor prediabetic and diabetic women while they are receiving hydroxyprogesterone caproate injection.

Because progestational drugs may cause some degree of fluid retention, carefully monitor women with conditions that might be influenced by this effect (e.g., preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction).

Monitor women who have a history of clinical depression and discontinue hydroxyprogesterone caproate injection if clinical depression recurs.

Carefully monitor women who develop jaundice while receiving hydroxyprogesterone caproate injection and consider whether the benefit of use warrants continuation.

Carefully monitor women who develop hypertension while receiving hydroxyprogesterone caproate injection and consider whether the benefit of use warrants continuation.

For the most serious adverse reactions to the use of progestins, see Warnings and Precautions ( 5 ).

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a vehicle (placebo)-controlled clinical trial of 463 pregnant women at risk for spontaneous preterm delivery based on obstetrical history, 310 received 250 mg of hydroxyprogesterone caproate injection and 153 received a vehicle formulation containing no drug by a weekly intramuscular injection beginning at 16 to 20 weeks of gestation and continuing until 37 weeks of gestation or delivery, whichever occurred first. [See Clinical Studies ( 14.1 ).]

Certain pregnancy-related fetal and maternal complications or events were numerically increased in the hydroxyprogesterone caproate injection-treated subjects as compared to control subjects, including miscarriage and stillbirth, admission for preterm labor, preeclampsia or gestational hypertension, gestational diabetes, and oligohydramnios (Tables 1 and 2).

Table 1 Selected Fetal Complications

N = Total number of subjects enrolled prior to 20 weeks 0 days N = Total number of subjects at risk ≥ 20 weeks

 

Table 2 Selected Maternal Complications

Other than delivery admission.

Common Adverse Reactions:

The most common adverse reaction with intramuscular injection was injection site pain, which was reported after at least one injection by 34.8% of the hydroxyprogesterone caproate injection group and 32.7% of the control group. Table 3 lists adverse reactions that occurred in ≥ 2% of subjects and at a higher rate in the hydroxyprogesterone caproate injection group than in the control group.

Table 3 Adverse Reactions Occurring in ≥ 2% of Hydroxyprogesterone Caproate Injection-Treated Subjects and at a Higher Rate than Control Subjects

In the clinical trial using intramuscular injection, 2.2% of subjects receiving hydroxyprogesterone caproate injection were reported as discontinuing therapy due to adverse reactions compared to 2.6% of control subjects. The most common adverse reactions that led to discontinuation in both groups were urticaria and injection site pain/swelling (1% each).

Pulmonary embolus in one subject and injection site cellulitis in another subject were reported as serious adverse reactions in hydroxyprogesterone caproate injection-treated subjects.

Pregnancy Complication Hydroxyprogesterone Caproate Injection n/N Control n/N
Miscarriage (< 20 weeks)1 5/209 0/107
Stillbirth (≥ 20 weeks)2 6/305 2/153
Pregnancy Complication Hydroxyprogesterone Caproate Injection
N=310
%
Control
N=153
%
Admission for preterm labor1 16.0 13.8
Preeclampsia or gestational hypertension 8.8 4.6
Gestational diabetes 5.6 4.6
Oligohydramnios 3.6 1.3
Preferred Term Hydroxyprogesterone Caproate Injection
N=310
%
Control
N=153
%
Injection site pain 34.8 32.7
Injection site swelling 17.1 7.8
Urticaria 12.3 11.1
Pruritus 7.7 5.9
Injection site pruritus 5.8 3.3
Nausea 5.8 4.6
Injection site nodule 4.5 2.0
Diarrhea 2.3 0.7

The following adverse reactions have been identified during postapproval use of hydroxyprogesterone caproate injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In vitro drug-drug interaction studies were conducted with hydroxyprogesterone caproate injection. Hydroxyprogesterone caproate has minimal potential for CYP1A2, CYP2A6, and CYP2B6 related drug-drug interactions at the clinically relevant concentrations. In vitro data indicated that therapeutic concentration of hydroxyprogesterone caproate is not likely to inhibit the activity of CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 [See Clinical Pharmacology ( 12.3 ).] No in vivo drug-drug interaction studies were conducted with hydroxyprogesterone caproate injection.

Risk Summary

Hydroxyprogesterone caproate injection is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. Fetal, neonatal, and maternal risks are discussed throughout labeling. Data from the placebo-controlled clinical trial and the infant follow-up safety study [see Clinical Studies (14.1, 14.2)] did not show a difference in adverse developmental outcomes between children of hydroxyprogesterone caproate injection-treated women and children of control subjects. However, these data are insufficient to determine a drug-associated risk of adverse developmental outcomes as none of the hydroxyprogesterone caproate injection-treated women received the drug during the first trimester of pregnancy. In animal reproduction studies, intramuscular administration of hydroxyprogesterone caproate to pregnant rats during gestation at doses 5 times the human dose equivalent based on a 60-kg human was not associated with adverse developmental outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Reproduction studies of hydroxyprogesterone caproate administered to various animal species have been reported in the literature. In nonhuman primates, embryolethality was reported in rhesus monkeys administered hydroxyprogesterone caproate up to 2.4 and 24 times the human dose equivalent, but not in cynomolgus monkeys administered hydroxyprogesterone caproate at doses up to 2.4 times the human dose equivalent, every 7 days between days 20 and 146 of gestation. There were no teratogenic effects in either strain of monkey.

Reproduction studies have been performed in mice and rats at doses up to 95 and 5, respectively, times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to hydroxyprogesterone caproate.

Risk Summary

Low levels of progestins are present in human milk with the use of progestin-containing products, including hydroxyprogesterone caproate. Published studies have reported no adverse effects of progestins on the breastfed child or on milk production.

Hydroxyprogesterone caproate injection is not indicated for use in women under 16 years of age. Safety and effectiveness in patients less than 16 years of age have not been established. A small number of women under age 18 years were studied; safety and efficacy are expected to be the same in women aged 16 years and above as for users 18 years and older [see Clinical Studies ( 14 )].

No studies have been conducted to examine the pharmacokinetics of hydroxyprogesterone caproate injection in patients with hepatic impairment. Hydroxyprogesterone caproate injection is extensively metabolized and hepatic impairment may reduce the elimination of hydroxyprogesterone caproate injection.

There have been no reports of adverse events associated with overdosage of hydroxyprogesterone caproate injection in clinical trials. In the case of overdosage, the patient should be treated symptomatically.

The active pharmaceutical ingredient in hydroxyprogesterone caproate injection is hydroxyprogesterone caproate, a progestin.

The chemical name for hydroxyprogesterone caproate is pregn-4-ene-3,20-dione, 17[(1-oxohexyl)oxy]. It has an empirical formula of CHO and a molecular weight of 428.60. Hydroxyprogesterone caproate exists as white to practically white crystals or powder with a melting point of 120°C to 124°C.

The structural formula is:

Hydroxyprogesterone caproate injection is a clear, yellow, sterile, non-pyrogenic solution for intramuscular injection. Each 1 mL single-dose vial contains hydroxyprogesterone caproate, 250 mg/mL (25% w/v), in a preservative-free solution containing castor oil (30.6% v/v) and benzyl benzoate (46% v/v).

Hydroxyprogesterone caproate is a synthetic progestin. The mechanism by which hydroxyprogesterone caproate reduces the risk of recurrent preterm birth is not known.

No specific pharmacodynamic studies were conducted with hydroxyprogesterone caproate injection.

Absorption: Female patients with a singleton pregnancy received intramuscular doses of 250 mg hydroxyprogesterone caproate for the reduction of preterm birth starting between 16 weeks 0 days and 20 weeks 6 days. All patients had blood drawn daily for 7 days to evaluate pharmacokinetics.

Table 4 Summary of Mean (Standard Deviation) Pharmacokinetics Parameters for Hydroxyprogesterone Caproate

Blood was drawn daily for 7 days (1) starting 24 hours after the first dose between Weeks 16 to 20 (Group 1), (2) after a dose between Weeks 24 to 28 (Group 2), or (3) after a dose between Weeks 32 to 36 (Group 3)

Reported as median (range)

t = 7 days

For all three groups, peak concentration (C) and area under the curve (AUC) of the mono-hydroxylated metabolites were approximately 3 to 8-fold lower than the respective parameters for the parent drug, hydroxyprogesterone caproate. While di-hydroxylated and tri-hydroxylated metabolites were also detected in human plasma to a lesser extent, no meaningful quantitative results could be derived due to the absence of reference standards for these multiple hydroxylated metabolites. The relative activity and significance of these metabolites are not known.

The elimination half-life of hydroxyprogesterone caproate, as evaluated from 4 patients in the study who reached full-term in their pregnancies, was 16.4 (+3.6) days. The elimination half-life of the mono-hydroxylated metabolites was 19.7 (+6.2) days.

In a single-dose, open-label, randomized, parallel design bioavailability study in 120 healthy post-menopausal women, comparable systemic exposure of hydroxyprogesterone caproate was seen when hydroxyprogesterone caproate injection was dosed intramuscularly (1 mL) in the upper outer quadrant of the gluteus maximus.

Distribution: Hydroxyprogesterone caproate binds extensively to plasma proteins including albumin and corticosteroid binding globulins.

Metabolism: In vitro studies have shown that hydroxyprogesterone caproate can be metabolized by human hepatocytes, both by phase I and phase II reactions. Hydroxyprogesterone caproate undergoes extensive reduction, hydroxylation and conjugation. The conjugated metabolites include sulfated, glucuronidated and acetylated products. In vitro data indicate that the metabolism of hydroxyprogesterone caproate is predominantly mediated by CYP3A4 and CYP3A5. The in vitro data indicate that the caproate group is retained during metabolism of hydroxyprogesterone caproate.

Excretion: Both conjugated metabolites and free steroids are excreted in the urine and feces, with the conjugated metabolites being prominent. Following intramuscular administration to pregnant women at 10 to 12 weeks gestation, approximately 50% of a dose was recovered in the feces and approximately 30% recovered in the urine.

Drug Interactions

Cytochrome P450 (CYP) enzymes: An in vitro inhibition study using human liver microsomes and CYP isoform-selective substrates indicated that hydroxyprogesterone caproate increased the metabolic rate of CYP1A2, CYP2A6, and CYP2B6 by approximately 80%, 150%, and 80%, respectively. However, in another in vitro study using human hepatocytes under conditions where the prototypical inducers or inhibitors caused the anticipated increases or decreases in CYP enzyme activities, hydroxyprogesterone caproate did not induce or inhibit CYP1A2, CYP2A6, or CYP2B6 activity. Overall, the findings indicate that hydroxyprogesterone caproate has minimal potential for CYP1A2, CYP2A6, and CYP2B6 related drug-drug interactions at the clinically relevant concentrations.

In vitro data indicated that therapeutic concentration of hydroxyprogesterone caproate is not likely to inhibit the activity of CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.

Group (N) Cmax (ng/mL) Tmax (days)a AUC(1 to t)b (ng•hr/mL)
Group 1 (N=6) 5.0 (1.5) 5.5 (2.0 to 7.0) 571.4 (195.2)
Group 2 (N=8) 12.5 (3.9) 1.0 (0.9 to 1.9) 1269.6 (285.0)
Group 3 (N=11) 12.3 (4.9) 2.0 (1.0 to 3.0) 1268.0 (511.6)

Hydroxyprogesterone caproate has not been adequately evaluated for carcinogenicity.

No reproductive or developmental toxicity or impaired fertility was observed in a multigenerational study in rats. Hydroxyprogesterone caproate administered intramuscularly, at gestational exposures up to 5 times the recommended human dose, had no adverse effects on the parental (F) dams, their developing offspring (F), or the latter offspring's ability to produce a viable, normal second (F) generation.

In a multicenter, randomized, double-blind, vehicle (placebo)-controlled clinical trial, the safety and effectiveness of hydroxyprogesterone caproate injection for the reduction of the risk of spontaneous preterm birth was studied in women with a singleton pregnancy (age 16 to 43 years) who had a documented history of singleton spontaneous preterm birth (defined as delivery at less than 37 weeks of gestation following spontaneous preterm labor or premature rupture of membranes). At the time of randomization (between 16 weeks, 0 days and 20 weeks, 6 days of gestation), an ultrasound examination had confirmed gestational age and no known fetal anomaly. Women were excluded for prior progesterone treatment or heparin therapy during the current pregnancy, a history of thromboembolic disease, or maternal/obstetrical complications (such as current or planned cerclage, hypertension requiring medication, or a seizure disorder).

A total of 463 pregnant women were randomized to receive either hydroxyprogesterone caproate injection (N=310) or vehicle (N=153) at a dose of 250 mg administered weekly by intramuscular injection starting between 16 weeks, 0 days and 20 weeks, 6 days of gestation, and continuing until 37 weeks of gestation or delivery. Demographics of the hydroxyprogesterone caproate injection-treated women were similar to those in the control group, and included: 59.0% Black, 25.5% Caucasian, 13.9% Hispanic and 0.6% Asian. The mean body mass index was 26.9 kg/m.

The proportions of women in each treatment arm who delivered at < 37 (the primary study endpoint), < 35, and < 32 weeks of gestation are displayed in Table 5.

Table 5 Proportion of Subjects Delivering at < 37, < 35 and < 32 Weeks Gestational Age (ITT Population)

Four hydroxyprogesterone caproate injection-treated subjects were lost to follow-up. They were counted as deliveries at their gestational ages at time of last contact (18, 22, 34 and 36 weeks).

Adjusted for interim analysis.

Compared to controls, treatment with hydroxyprogesterone caproate injection reduced the proportion of women who delivered preterm at < 37 weeks. The proportions of women delivering at < 35 and < 32 weeks also were lower among women treated with hydroxyprogesterone caproate injection. The upper bounds of the confidence intervals for the treatment difference at < 35 and < 32 weeks were close to zero. Inclusion of zero in a confidence interval would indicate the treatment difference is not statistically significant. Compared to the other gestational ages evaluated, the number of preterm births at < 32 weeks was limited.

After adjusting for time in the study, 7.5% of hydroxyprogesterone caproate injection-treated subjects delivered prior to 25 weeks compared to 4.7% of control subjects; see Figure 1.

Figure 1 Proportion of Women Remaining Pregnant as a Function of Gestational Age

The rates of fetal losses and neonatal deaths in each treatment arm are displayed in Table 6. Due to the higher rate of miscarriages and stillbirths in the hydroxyprogesterone caproate injection arm, there was no overall survival difference demonstrated in this clinical trial.

Table 6 Fetal Losses and Neonatal Deaths

Four of the 310 hydroxyprogesterone caproate injection-treated subjects were lost to follow-up and stillbirth or neonatal status could not be determined Percentages are based on the number of enrolled subjects and not adjusted for time on drug Percentage adjusted for the number of at risk subjects (n=209 for hydroxyprogesterone caproate injection, n=107 for control) enrolled at <20 weeks gestation.

A composite neonatal morbidity/mortality index evaluated adverse outcomes in livebirths. It was based on the number of neonates who died or experienced respiratory distress syndrome, bronchopulmonary dysplasia, grade 3 or 4 intraventricular hemorrhage, proven sepsis, or necrotizing enterocolitis. Although the proportion of neonates who experienced 1 or more events was numerically lower in the hydroxyprogesterone caproate injection arm (11.9% vs. 17.2%), the number of adverse outcomes was limited and the difference between arms was not statistically significant.

Delivery Outcome Hydroxyprogesterone Caproate Injection1
(N=310)
%
Control
(N=153)
%
Treatment difference and
95% Confidence Interval2
<37 weeks 37.1 54.9 -17.8% [-28.0%, -7.4%]
<35 weeks 21.3 30.7 -9.4% [-19.0%, -0.4%]
<32 weeks 11.9 19.6 -7.7% [-16.1%, -0.3%]
Complication Hydroxyprogesterone Caproate Injection
N=306 A
n (%) B
Control
N=153
n (%) B
Miscarriages <20 weeks gestation C 5 (2.4) 0
Stillbirth 6 (2.0) 2 (1.3)
Antepartum stillbirth 5 (1.6) 1 (0.6)
Intrapartum stillbirth 1 (0.3) 1 (0.6)
Neonatal deaths 8 (2.6) 9 (5.9)
Total Deaths 19 (6.2) 11 (7.2)

Infants born to women enrolled in this study, and who survived to be discharged from the nursery, were eligible for participation in a follow-up safety study. Of 348 eligible offspring, 79.9% enrolled: 194 children of hydroxyprogesterone caproate injection-treated women and 84 children of control subjects. The primary endpoint was the score on the Ages & Stages Questionnaire (ASQ), which evaluates communication, gross motor, fine motor, problem solving, and personal/social parameters. The proportion of children whose scores met the screening threshold for developmental delay in each developmental domain was similar for each treatment group.

Hydroxyprogesterone caproate injection, USP (NDC 0517-1767-01) is supplied as 1 mL of a sterile preservative-free clear yellow solution in a single-dose glass vial.

Each 1 mL vial contains hydroxyprogesterone caproate, 250 mg/mL (25% w/v), in castor oil (30.6% v/v) and benzyl benzoate (46% v/v).

Single unit carton: Contains one 1 mL single-dose vial of hydroxyprogesterone caproate injection containing 250 mg of hydroxyprogesterone caproate.

Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not refrigerate or freeze.

Caution: Protect vial from light. Store vial in its box. Store upright.

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Counsel patients that hydroxyprogesterone caproate injections may cause pain, soreness, swelling, itching or bruising. Inform the patient to contact her physician if she notices increased discomfort over time, oozing of blood or fluid, or inflammatory reactions at the injection site [see Adverse Reactions (6.1) ].

AMERICANREGENT, INC.SHIRLEY, NY  11967 07/2018

RQ107801

Hydroxyprogesterone Caproate (hye droks ee proe JES te rone CAP ro ate) Injection

Hydroxyprogesterone caproate injection 250 mg/mL

Read this Patient Information Leaflet before you receive hydroxyprogesterone caproate injection. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is hydroxyprogesterone caproate injection?

Hydroxyprogesterone caproate injection is a prescription hormone medicine (progestin) used in women who are pregnant and who have delivered a baby too early (preterm) in the past. Hydroxyprogesterone caproate injection is used in these women to help lower the risk of having a preterm baby again. It is not known if hydroxyprogesterone caproate injection reduces the number of babies who are born with serious medical conditions or die shortly after birth.

Hydroxyprogesterone caproate injection is for women who:

Hydroxyprogesterone caproate injection is not intended for use to stop active preterm labor.

It is not known whether hydroxyprogesterone caproate injection is safe and effective in women who have other risk factors for preterm birth.

Hydroxyprogesterone caproate injection is not for use in women under 16 years old.

Who should not receive hydroxyprogesterone caproate injection?

Hydroxyprogesterone caproate injection should not be used if you have:

  What should I tell my healthcare provider before receiving hydroxyprogesterone caproate injection?

Before you receive hydroxyprogesterone caproate injection, tell your healthcare provider about all of your medical conditions, including if you have:

How should I receive hydroxyprogesterone caproate injection?

What are the possible side effects of hydroxyprogesterone caproate injection?

Hydroxyprogesterone caproate injection may cause serious side effects, including:

Call your healthcare provider right away if you get any of the symptoms above during treatment with hydroxyprogesterone caproate injection.

The most common side effects of hydroxyprogesterone caproate injection include:

Call your healthcare provider if you have the following at your injection site:

Other side effects that may happen more often in women who receive hydroxyprogesterone caproate include:

Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.

How should I store hydroxyprogesterone caproate injection?

Keep hydroxyprogesterone caproate injection and all medications out of the reach of children

General information about the safe and effective use of hydroxyprogesterone caproate injection.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use hydroxyprogesterone caproate injection for a condition for which it was not prescribed. Do not give hydroxyprogesterone caproate injection to other people, even if they have the same symptoms you have. It may harm them.

This leaflet summarizes the most important information about hydroxyprogesterone caproate injection. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about hydroxyprogesterone caproate injection that is written for health professionals.

What are the ingredients in hydroxyprogesterone caproate injection?

Active ingredient: hydroxyprogesterone caproateInactive ingredients: castor oil and benzyl benzoate.

AMERICANREGENT, INC.SHIRLEY, NY 11967 For more information, go to www.americanregent.com or call American Regent at the toll free number 1-800-734-9236. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised 07/2018

NDC 0517-1767-01

Rx Only Hydroxyprogesterone Caproate Injection, USP 250 mg/mL 1 mL Single Dose Vial FOR INTRAMUSCULAR USE AMERIAN REGENT, INC.SHIRLEY, NY  11967

NDC 0517-1767-01 Hydroxyprogesterone Caproate Injection, USP 250 mg/mL 1 mL Vial FOR INTRAMUSCULAR USE 1 mL Single Dose Vial Rx Only AMERICAN REGENT, INC.SHIRLEY, NY  11967

Manufacturer

American Regent, Inc.

Active Ingredients

Source

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Hydroxyprogesterone caproate [slayback pharma llc]

These highlights do not include all the information needed to use HYDROXYPROGESTERONE CAPROATE INJECTION safely and effectively. See full prescribing information for HYDROXYPROGESTERONE CAPROATE INJEC...

Hydroxyprogesterone caproate [prasco laboratories]

These highlights do not include all the information needed to use HYDROXYPROGESTERONE CAPROATE INJECTION safely and effectively. See full prescribing information for HYDROXYPROGESTERONE CAPROATE INJEC...

Hydroxyprogesterone caproate [mylan institutional llc]

Makena [amag pharmaceuticals, inc.]

These highlights do not include all the information needed to use MAKENA safely and effectively. See full prescribing information for MAKENA. MAKENA® (hydroxyprogesterone caproate injection) for intr...

Clinical Trials [22 Associated Clinical Trials listed on BioPortfolio]

A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix

We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when compared to ...

17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor

Preterm deliveries play a significant role in neonatal morbidity and mortality. Previous studies showed that administration of progesterone to pregnant women at high risk, decrease spontan...

Treatment of Preterm Labor With 17 Alpha-Hydroxyprogesterone Caproate

The goal of our research will be to determine the effectiveness of 17 alpha-hydroxyprogesterone caproate (17P) in the treatment of preterm delivery. Treatment with progesterone is emergin...

17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa

Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Pr...

Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa

Purpose to evaluate the effects of Vaginal Progesterone versus 17-Alpha-Hydroxyprogesterone Caproate for prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women with Placen...

PubMed Articles [18 Associated PubMed Articles listed on BioPortfolio]

Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.

To evaluate whether there are additional benefits of 17-hydroxyprogesterone caproate (17-OHPC) supplementation in preventing recurrent spontaneous preterm birth in women with a prophylactic cerclage.

Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.

 Weekly 17-hydroxyprogesterone caproate (17OHP-C) from 16 to 36 weeks' gestation reduces the risk of recurrent spontaneous preterm birth (sPTB). Limited data suggest poor adherence to published guid...

Defining the Clinical Response to 17-alpha hydroxyprogesterone Caproate.

An efficient biotransformation of progesterone into 11α-hydroxyprogesterone by Rhizopus microsporus var. oligosporus.

Rhizopus microsporus var. oligosporus is a fungus that belongs to the Mucoraceae family that is used for the preparation of some soy-fermented foods. Microbial biotransformation of progesterone by R. ...

Biotransformation into 11α-hydroxyprogesterone glucosides by glucosyltransferase.

Recently, studies on the steroidal hormone activity in the brain have attracted attention, and the influences of the varied glucosides and their artificial derivatives have been discussed; additionall...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Obstetrics and gynaecology
Fertility Menopause Obstetrics & Gynaecology Osteoporosis Women's Health Obstetrics and gynaecology comprises the care of the pregnant woman, her unborn child and the management of diseases specific to women. Most consultant...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record